Table 1

Clinical and biochemical characteristics of the study cohort stratified according to use of statins during follow-up period

Non–statin usersStatin usersP
n3,7931,483
Baseline variables and outcomes
    Age (years)56 (22)58 (18)<0.0001*
    Male sex1,794 (47.3%)676 (45.6%)0.2619
    Smoking status0.5662
        Ex-smoker559 (14.7%)231 (15.6%)
        Current smoker594 (15.7%)242 (16.3%)
    Alcohol drinking status0.4829
        Ex-drinker457 (12.1%)187 (12.6%)
        Current drinker298 (7.9%)103 (7.0%)
    BMI, kg/m224.6 (4.9)25.0 (4.8)<0.0001*
    Duration of diabetes (years)5 (9)7 (10)<0.0001*
    Systolic blood pressure (mmHg)132 (25)138 (27)<0.0001*
    Diastolic blood pressure (mmHg)75 (14)76 (14)<0.0001*
    A1C (%)7.0 (2.0)7.7 (2.2)<0.0001*
    LDL cholesterol (mmol/l)2.90 (1.06)3.71 (1.15)<0.0001*
    HDL cholesterol (mmol/l)1.27 (0.47)1.22 (0.42)<0.0001*
    Triglycerides (mmol/l)1.21 (0.88)1.58 (1.11)<0.0001*
    Total cholesterol (mmol/l)4.90 (1.17)5.80 (1.30)<0.0001*
    ACR (mg/mmol)1.63 (6.03)3.78 (25.5)<0.0001*
    LDL cholesterol <2.80 mmol/l plus albuminuria594 (15.7%)101 (6.8%)<0.0001
    eGFR (ml/min per 1.73 m2)107.2 (40.4)99.4 (43.0)<0.0001*
    Prior myocardial infarction21 (0.6%)31 (2.1%)<0.0001
    Prior stroke112 (3.0%)86 (5.8%)<0.0001
    Cancer during follow-up210 (5.5%)34 (2.3%)<0.0001
    Death (all-cause) during follow-up337 (8.9%)103 (7.0%)0.0220
Medications at enrollment
    Fibrates83 (2.2%)95 (6.4%)<0.0001
    Oral antidiabetes drugs2,402 (63.3%)1,022 (68.9%)0.0001
    Insulin562 (14.8%)350 (23.6%)<0.0001
    ACEIs or ARBs689 (18.2%)427 (28.8%)<0.0001
    Antihypertensive drugs other than ACEIs or ARBs1,270 (33.5%)591 (39.9%)<0.0001
Medications during follow-up period
    Fibrates282 (7.4%)251 (16.9%)<0.0001
    Oral antidiabetes drugs3,076 (81.1%)1,343 (90.6%)<0.0001
    Insulin1,114 (29.4%)794 (53.5%)<0.0001
    ACEIs or ARBs1,777 (46.9%)1,109 (74.8%)<0.0001
Duration of use of statins (years)2.07 (3.18)
  • Data are median (25th–75th percentiles) or n (%). Albuminuria was defined as spot urinary ACR ≥2.5 mg/mmol in men and ≥3.5 mg/mmol in women.

  • *Derived from a Wilcoxon two-sample test.

  • †Derived from a χ2 test.

  • ‡From baseline to cancer, death, or censoring dates whichever came first.